NCT02626234 - A Drug-drug Interaction (DDI) Study to Assess the Effect of INC280 on the Pharmacokinetics of Digoxin and Rosuvastatin in Patients With cMET-dysregulated Advanced Solid Tumors | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 8, 2015

Primary Completion Date

February 28, 2017

Study Completion Date

April 28, 2017

Conditions

cMET-dysregulated Advanced Solid Tumors

Interventions

DRUG

INC280

DRUG

digoxin

DRUG

rosuvastatin

Trial Locations (15)

2650

Novartis Investigative Site, Edegem

10060

Novartis Investigative Site, Candiolo

18547

Novartis Investigative Site, Athens

20141

Novartis Investigative Site, Milan

28034

Novartis Investigative Site, Madrid

28222

Novartis Investigative Site, Madrid

30322

Emory University School of Medicine/Winship Cancer Institute Phase 1 Working Group, Atlanta

40138

Novartis Investigative Site, Bologna

65653

Novartis Investigative Site, Brno

80131

Novartis Investigative Site, Napoli

03756

Dartmouth Hitchcock Medical Center, Lebanon

A-1090

Novartis Investigative Site, Vienna

455 00

Novartis Investigative Site, Ioannina

W1G 6AD

Novartis Investigative Site, London

M20 9BX

Novartis Investigative Site, Manchester